In animal models of heart failure, previous studies demonstrated that Treg cells could be a target of heart failure therapeutics because CCR5-mediated Treg-cell recruitment in the infarcted heart [15] and adoptively transferred Treg cells [16] provided protection from adverse cardiac remodeling by preventing expansion of inflammation and fibrosis after adoptive transfer. This evidence concerns the gene CCR5 and heart failure.